Trial Profile
Phase 1 Clinical Trial of rAAV2.5-CMV-mini-Dystrophin Gene Vector in Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Minidystrophin gene therapy (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- 21 May 2014 New trial record